Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

ETHK Labs Inc.
華檢醫療控股有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 1931)

CHANGE IN COMPOSITION OF THE BOARD OF DIRECTORS AND ITS COMMITTEES, COMPANY SECRETARY AND AUTHORISED REPRESENTATIVE

CHANGE IN COMPOSITION OF THE BOARD AND ITS COMMITTEES

ETHK Labs Inc. (the "**Company**") announces that the following changes in the composition of its board (the "**Board**") of directors (the "**Directors**") have taken effect from 10 November 2026:

Mr. Chan Siu Kei Ken ("**Mr. Chan**") resigned as an executive Director due to other business pursuit. He also resigned from his other positions in the Company as the company secretary (the "**Company Secretary**") and an authorised representative of the Company (the "**Authorised Representatives**") pursuant to Rule 3.05 of the Rules (the "**Listing Rules**") Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**"), and an authorized representative for accepting service of process and notices on behalf of the Company in Hong Kong as required under Part 16 of the Companies Ordinance (Chapter 622 of the Laws of Hong Kong) (the "**Companies Ordinance**").

Mr. Chan has confirmed that he has no disagreement with the Board and there are no matters relating to his resignation that need to be brought to the attention of the Stock Exchange and the shareholders of the Company.

In light of the resignation of Mr. Chan, the following changes to the Board Committees have taken effect have taken effect on 10 November 2026:

1. Mr. Chan ceased to be a member of the nomination committee of the Company (the "**Nomination Committee**");

2. Mr. Wong Ka Sing ("**Mr. Wong**") has been appointed as a member of the Nomination Committee.

The Company thanks Mr. Chan for his contributions during his tenure and welcomes Mr. Wong to the Board.

APPOINTMENT OF EXECUTIVE DIRECTOR, COMPANY SECRETARY AND AUTHORISED REPRSENTATIVE

The Board also announces that Mr. Wong has been appointed as the executive Director, the Company Secretary, one of the Authorised Representatives for the purpose of the Listing Rules and the authorised representative for accepting service of process and notices on behalf of the Company in Hong Kong as required under Part 16 of the Companies Ordinance (Chapter 622 of the Laws of Hong Kong) with effect from 10 November 2026. Mr. Wong meets the qualification requirements of a company secretary under Rule 3.28 of the Listing Rules.

Mr. Wong, aged 39, obtained a degree of Master of Finance from University of Hong Kong and a degree of Bachelor of Business Administration in Accountancy from City University of Hong Kong. Mr. Wong is currently a member of the Hong Kong Institute of Certified Public Accountants and is also a licensed person registered under the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the "**SFO**") to carry out Type 6 (advising on corporate finance) regulated activity. Mr. Wong has extensive experience in corporate governance, corporate finance, compliance advising, company secretarial work, accounting, auditing and internal controls.

Mr. Wong is currently (i) the executive director and the responsible officer of First Global Corporate Finance Co., Limited, a licensed corporation registered under the SFO to carry out Type 6 (advising on corporate finance) regulated activity, since March 2025; (ii) the joint company secretary and authorised representative of Diwang Industrial Holdings Limited (Stock code: 1950) since June 2024; (iii) the company secretary and authorised representative of King International Investment Limited (stock code: 928) since March 2024; (iv) the company secretary and authorized representative of China Frontier Technology Group (stock code: 1661) since July 2024; and (v) the independent non-executive Director of Kwong Man Kee Group Limited (stock code: 8023) since September 2026.

In accordance with the Company's articles of association, Mr. Wong will hold office as a Director until the next annual general meeting of the Company (and be eligible for re-election). It is expected that Mr. Wong will enter into a service agreement with the Company, subject to termination by either party's three-month notice. His tenure is also subject to other provisions relating to termination, retirement and re-election in the service agreement and under the Company's articles of association.

It is expected that under the service agreement, Mr. Wong will be entitled to a monthly director's remuneration of HK$100,000, and is eligible to receive discretionary bonuses, other benefits and allowances (including the Group's contribution of applicable provident fund and share scheme). Mr. Wong's remuneration was recommended by the remuneration committee of the Company and approved by the Board in accordance with the Company's remuneration policy for Directors, with reference to his roles, duties and responsibilities, his background, as well as the comparable market practice, and is subject to revision in future by the decision of the Board based on the recommendation of the remuneration committee of the Company.

Mr. Wong confirmed that, save as disclosed in this announcement, (i) he does not have any relationship with any of the Directors, senior management or substantial or controlling shareholders of the Company (as defined under the Listing Rules) as at the date of this announcement; (ii) he has not held any other directorships in other public companies the securities of which are listed on any securities market in Hong Kong or overseas in the preceding three years; (iii) he does not have any interests in the shares of the Company within the meaning of Part XV of the SFO; and (iv) there is no other information required to be disclosed pursuant to Rule 13.51(2) of the Listing Rules. The Company is not aware of any other matters relating to Mr. Wong's appointment that need to be brought to the attention of the shareholders of the Company.

Mr. Wong has obtained the legal advice referred to in Rule 3.09D of the Listing Rules on 30 October 2026, and has confirmed that he understood his obligations as a director of a listed issuer on the same date.

By order of the Board
ETHK Labs Inc.
Lin Xianya
Executive Director

Hong Kong, 10 November 2026

As at the date of this announcement, the Board comprises three executive directors, namely, Mr. Lin Xianya, Mr. Wong Ka Sing and Ms. Yi Xiao, two non-executive directors, namely, Ms. Yao Haiyun and Mr. Liu Fei and three independent non-executive directors, namely, Dr. Zhong Renqian, Mr. Xu Da, and Mr. Zhang Jianlei.